MorphoSys (NASDAQ:MOR) Stock Rating Reaffirmed by Leerink Pa

Leerink Partnrs reiterated their market perform rating on shares of MorphoSys (NASDAQ:MOR – Free Report) in a research note published on Wednesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for MorphoSys’ FY2026 earnings at ($0.78) EPS. A number of other research analysts have also recently weighed in on MOR. Morgan Stanley raised MorphoSys from […]

Related Keywords

United States , Leerink Partnrs , Morgan Stanley , Blackrock Inc , Virtu Financial , Qube Research Technologies Ltd , Jpmorgan Chase Co , Goldman Sachs Group , Free Report , Get Free Report , Technologies Ltd , Morphosys Daily , Morphosys , Nasdaq Mor , Humor , Medical , Reiterated Rating ,